Merus to Participate in Upcoming Investor Conferences
Get Alerts MRUS Hot Sheet
Join SI Premium – FREE
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
- Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One Madison Avenue in New York City.
- Management will participate in investor meetings at Citi’s 11th Annual Biotech Conference on Thursday, September 8 at the Mandarin Oriental in Boston.
A live webcast of the Credit Suisse presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
About Merus N.V.Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Merus N.V. Shelley Margetson – [email protected] +31 (0)30 253 8800 Argot Partners Kimberly Minarovich – [email protected] 1-212-600-1902Source: Merus N.V.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto Projects Don’t Need Louder Marketing They Need Searchable Trust
- New Jersey Digital Agency Synaryverse Integrates AI Into Marketing, Development, and Creative Services
- Green Mobility in Africa — UNDP and TAILG Sign MOU for a Green, Low-Carbon Mobility Project to Advance Sustainable Development in Africa and Beyond
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Credit Suisse, CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share